AIM ImmunoTech is a pharmaceutical company that researches and develops novel therapeutics to treat cancer and immune-deficiency disorders. Read more

5 Followers on Owler
5 Followers on Owler
5 Followers on Owler
5 Followers on Owler

AIM ImmunoTech is a pharmaceutical company that researches and develops novel therapeutics to treat cancer and immune-deficiency disorders. Read more

Thomas K. Equels's photo - President & CEO of AIM ImmunoTech

President & CEO

Thomas K. Equels

CEO Approval Rating

90/100

Founded:

1990

Status:

PublicIndependent CompanyNYSEAIM

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

NexImmune is a top competitor of AIM ImmunoTech. NexImmune was founded in Gaithersburg, Maryland} in 2011. NexImmune competes in the Biotechnology industry. Compared to AIM ImmunoTech, NexImmune generates $21.7M more revenue.

Aura Biosciences is AIM ImmunoTech's #2 competitor. Aura Biosciences is headquartered in Cambridge, Massachusetts, and was founded in 2009. Aura Biosciences competes in the Biotechnology field. Aura Biosciences generates 13,454% the revenue of AIM ImmunoTech.

Jounce has been one of AIM ImmunoTech's top competitors. Jounce is a Public company that was founded in 2012 in Cambridge, Massachusetts. Like AIM ImmunoTech, Jounce also competes in the Biotechnology industry. Compared to AIM ImmunoTech, Jounce has 97 more employees.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Apple a competitor of AIM ImmunoTech?

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$ < 1M

AIM ImmunoTech's revenue is the ranked 4th among it's top 10 competitors. The top 10 competitors average 49M. Over the last two quarters, AIM ImmunoTech's revenue has decreased by 11.1%. Specifically, in Q2 2020's revenue was $ < 1M; in Q1 2020, it was $ < 1M.

Acquisitions

No recent acquisitions found related to AIM ImmunoTech

AIM ImmunoTech Funding History

$33.3K$51.5K$77.3K

Since AIM ImmunoTech was founded in 1990, it has participated in 3 rounds of funding. In total AIM ImmunoTech has raised $77.3K. AIM ImmunoTech's last funding round was on Apr 2018 for a total of $25.7K

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Unattributed
Apr 2018
$25.7K
-
Unattributed
Feb 2017
$18.2K
-
Unattributed
Aug 2016
$33.3K
-

Since AIM ImmunoTech was founded in 1990, it has participated in 3 rounds of funding. In total AIM ImmunoTech has raised $77.3K. AIM ImmunoTech's last funding round was on Apr 2018 for a total of $25.7K

Investments

No recent investments found related to AIM ImmunoTech

AIM ImmunoTech News

December 24, 2020Proactive Investors

AIM ImmunoTech enrolling patients in coronavirus-induced chronic fatigue trial of Ampligen

The company is authorized to enroll up to 100 active trial participants, 20 of whom can be long haule... See more »
December 21, 2020Proactive Investors

AIM ImmunoTech drug Ampligen gets FDA orphan status as pancreatic cancer treatment

The designation gives AIM seven years of exclusivity rights after Ampligen reaches market... See more »
November 25, 2020FinanzNachrichten

AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as Part of Combination Treatment for Patients with Cancer and COVID-19

OCALA, Fla., Nov. 25, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announc... See more »
November 13, 2020BioSpace

AIM ImmunoTech Provides Third Quarter 2020 Business Update

AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and develo... See more »
November 2, 2020Proactive Investors

AIM ImmunoTech says data validating Ampligen as chronic fatigue treatment published in medical journal, expands study to include coronavirus 'long haulers'

Ampligen substantially improved physical performance in a subset of ME/CFS patients... See more »
October 30, 2020South Florida Citybizlist

BioFlorida Names AIM ImmunoTech CEO Thomas K. Equels as Entrepreneur of the Year

BioFlorida has announced Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech Inc. (NYSE Ameri... See more »
October 30, 2020Proactive Investors

AIM ImmunoTech CEO Thomas Equels named Entrepreneur of the Year by BioFlorida

The Entrepreneur of the Year Award recognizes those who have made extraordinary contributions to the ... See more »

AIM ImmunoTech Blogs

May 29, 2020AIM ImmunoTech Blog

AIM ImmunoTech Describes Their Approach and Progress with Ampligen to Combat COVID-19

AIM ImmunoTech Describes Their Approach and Progress with Ampligen to Combat COVID-19 SNNLive caugh... See more »
March 9, 2020AIM ImmunoTech Blog

AIM ImmunoTech Reaches Deal with Japan’s National Institute of Infectious Diseases to Test Ampligen as a Potential Treatment for Coronavirus

AIM ImmunoTech Reaches Deal with Japan's National Institute of Infectious Diseases to Test Ampligen a... See more »
August 15, 2019AIM ImmunoTech Blog

Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical Trials

Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical Trials ... See more »
July 9, 2019AIM ImmunoTech Blog

Prostate Cancer News Today Provides an Ampligen Upate

Prostate Cancer News Today Provides an Ampligen Update We recently announced that the Roswell Park Co... See more »
May 28, 2019AIM ImmunoTech Blog

Ovarian Cancer News Today Updates Readers on Ampligen Trials

Ovarian Cancer News Today Updates Readers on Ampligen Trials Ovarian Cancer News Today recently featu... See more »
April 5, 2019AIM ImmunoTech Blog

CEO Roadshow Interviews Hemispherx Thomas K. Equels

CEO Roadshow Interviews Hemispherx Thomas K. Equels Hemispherx CEO Thomas K. Equels recently sat down... See more »
March 26, 2019AIM ImmunoTech Blog

Introducing You to the First Ampligen Quarterly Update

Introducing You to the First Ampligen Quarterly Update Today we announced significant progress in our... See more »

AIM ImmunoTech Press Releases

March 31, 2020StreetInsider

AIM ImmunoTech Reports 2019 Year-end Financial Results

OCALA, FL / ACCESSWIRE / March 31, 2020 / AIM ImmunoTech (NYSE American:AIM) announces financial resu... See more »
February 13, 2020PR-Inside

AIM ImmunoTech Files Three Provisional Patent Applications Surrounding ...

(PR-inside.com) Ampligen® obtained 100% survival rate at clinically achievable human dosage levels fo... See more »
October 28, 2019Network Newswire

AIM) Starts Presentation at Dawson James Small Cap Growth Conference - NetworkNewsWire

AIM ImmunoTech Inc. (NYSE: AIM) is an immuno-pharma company focused on the research and development o... See more »
September 10, 2019StreetInsider

AIM ImmunoTech Announces Progress Toward Opening of Breast Cancer Study at Roswell Park Comprehensive Cancer Center

OCALA, FL / ACCESSWIRE / September 10, 2019 / AIM ImmunoTech Inc., (NYSE American:AIM), an immuno-pha... See more »
August 15, 2019GlobeNewswire

Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical Trials

OCALA, Fla., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an im... See more »
August 8, 2019GlobeNewswire

Hemispherx Reports Positive Safety and Survival Data in Phase 1 Stage 4 Ovarian Cancer Clinical Study Using Ampligen®

OCALA, Fla., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American: HEB) announced to... See more »

AIM ImmunoTech Videos

Social Media

Headquarters

2117 SW Highway 484

Ocala, Florida34473

212-671-1021

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

AIM ImmunoTech is a pharmaceutical company that researches and develops novel therapeutics to treat cancer and immune-deficiency disorders. AIM ImmunoTech was founded in 1990. AIM ImmunoTech's headquarters is located in Ocala, Florida, USA 34473. It h...

CEO

AIM ImmunoTech's President & CEO, Thomas K. Equels, currently has an approval rating of 90%. AIM ImmunoTech's primary competitors are NexImmune, Aura Biosciences & Jounce.

Website

aimimmuno.com

Frequently Asked Questions about AIM ImmunoTech

  1. When was AIM ImmunoTech founded?

    AIM ImmunoTech was founded in 1990
  2. Who is AIM ImmunoTech's CEO?

    AIM ImmunoTech's CEO is Thomas K. Equels
  3. How much revenue does AIM ImmunoTech generate?

    AIM ImmunoTech generates $ < 1M in revenue
  4. How much funding does AIM ImmunoTech have?

    AIM ImmunoTech has historically raised $77.3K in funding
  1. Where is AIM ImmunoTech's headquarters?

    AIM ImmunoTech's headquarters is in Ocala Florida, USA
  2. How many employees does AIM ImmunoTech have?

    AIM ImmunoTech has 32 employees
  3. What sector does AIM ImmunoTech operate in?

    AIM ImmunoTech is in Biotechnology
  4. Who are AIM ImmunoTech's competitors?

    AIM ImmunoTech's top competitors are NexImmune, Aura Biosciences, Jounce